

SYNOPSIS

Name of Sponsor/Company: Mutual Pharmaceutical Co., Inc. 1100 Orthodox Street Philadelphia, PA 19124	Page 1 of 2	Mutual Pharmaceutical Company, Inc <i>This report is the property of Mutual Pharmaceutical Company, Inc, and may not be used without the permission of Mutual Pharmaceutical Co., Inc.</i>
Name of Finished Product: Lovastatin Tablets 40mg	Report Date: October 2004	
Name of Active Ingredient: lovastatin	Final Report Number: LVI-P4-126	
Title of Study: A Single Dose Crossover Comparative Bioavailability Study of Lovastatin 40mg Tablets in Healthy Male Volunteers / Fed State		
Investigators: Eric Sicard, M.D., Clinical Investigator Christian Aumais, M.D., Sub-Investigator		
Study Center(s): Algorithme Pharma Inc. (Clinical) 9000 Boulevard de L'Acadie Montreal, Quebec, Canada H4N 2Y8 Bioassay (Bioanalytical) 10550 Rockley Road Suite 150 Houston, Texas 77099		
Study dates: Period I: July 15, 2004 Period II: July 22, 2004	Phase of development: Phase 1	
Objectives: Evaluate and compare the relative bioavailability and therefore the bioequivalence of two formulations of lovastatin after a single oral dose administration under fed conditions.		
Number of patients: enrolled: 54 completed: 54		
Test product (A): Mutual Pharmaceutical's Lovastatin Tablets Dose: 40mg Mode of administration: Oral Batch number: BB 534 0129 Reference product (B): Mevacor® Tablets Dose: 40mg Mode of administration: Oral Batch number: P4016		

Name of Sponsor/Company: Mutual Pharmaceutical Co., Inc. 1100 Orthodox Street Philadelphia, PA 19124	Page 2 of 2	Mutual Pharmaceutical Company, Inc <i>This report is the property of Mutual Pharmaceutical Company, Inc, and may not be used without the permission of Mutual Pharmaceutical Co., Inc.</i>
Name of Finished Product: Lovastatin Tablets 40mg	Report Date: October 2004	
Name of Active Ingredient: lovastatin	Final Report Number: LVI-P4-126	

Criteria for evaluation: Bioequivalence

SUMMARY – CONCLUSIONS

Bioequivalence: Mutual Pharmaceutical’s Lovastatin Tablets, 40mg were bioequivalent to Merck & Co., Inc.’s Mevacor® Tablets, 40mg on the basis of C_{max} , AUC_T and AUC_{∞} parameters of lovastatin.

PARAMETER	GEOMETRIC LS MEANS		RATIO	90% CONFIDENCE LIMITS	
	TEST	REFERENCE		LOWER	UPPER
C_{max}	5.79	6.24	92.69	81.99	104.79
AUC_T	24.85	26.36	94.27	87.58	101.47
AUC_{∞}	25.78	27.64	93.27	86.17	100.95